Navigation Links
Xenon Receives a Milestone Payment for Marketing Approval of Glybera in Europe
Date:2/5/2013

VANCOUVER, British Columbia, Feb. 5, 2013 /PRNewswire/ -- Xenon, a clinical stage biopharmaceutical company developing novel therapeutics for rare diseases, today announced that it has received a milestone payment from uniQure BV for the European Commission marketing approval of Glybera®, a novel gene therapy treatment for the orphan disease lipoprotein lipase deficiency (LPLD), and the first gene therapy approved in the Western world.

Xenon exclusively licensed to uniQure BV its rights to the LPLS447X genetic variant that causes a gain of function in the lipoprotein lipase (LPL) gene in humans.  Humans with the LPLS447X variant have been shown on average to have lower triglyceride and higher HDL cholesterol levels than those without LPLS447X.  Glybera developed by uniQure is an adeno-associated virus based human gene therapy that contains LPLS447X and in clinical studies Glybera was effective in reducing blood fat levels and episodes of pancreatitis in patients with LPLD.

"The approval of Glybera is an important milestone for our Company and for the gene therapy field in general," said Simon Pimstone , President and CEO of Xenon. "Xenon was founded with a commitment to advancing human genetic discoveries into novel therapies for difficult to treat orphan diseases and Glybera is the first product to be marketed by one of our licensees."

In addition to the milestone payment Xenon is also entitled to receive from uniQure BV royalty payments on sales of Glybera, which is expected to start selling in Europe in 2013. The LPLS447X technology in Glybera was conceived and developed by Xenon's former CSO Michael Hayden at the Center of Molecular Medicine, University of British Columbia.

About Xenon Pharmaceuticals Inc. (Xenon)

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing novel therapies for rare diseases. For more information, visit the Company's website at http://www.xenon-pharma.com.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

Xenon Pharmaceuticals Inc., 200- 3650 Gilmore Way, Burnaby, British Columbia, V5G 4W8, Canada, www.xenon-pharma.com


'/>"/>
SOURCE Xenon Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. In search for a vaccine, IU biologist receives $2.3 million to explore chlamydia genomics
2. Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award
3. UF receives $1 million from Keck Foundation to study mechanisms of inherited disease
4. Gladstone scientist Warner C. Greene receives Washington University School of Medicine Alumni Award
5. Carnegies Wolf B. Frommer receives Bogorad Award for Excellence in Plant Biology
6. UC Riverside plant cell biologist receives top scientific honor
7. UC Riverside receives grant for global health and development research
8. Washington University receives $8 million to lead international childhood malnutrition effort
9. SRI Sarnoffs Iris on the Move® N-Glance™ Identification System Receives Lenel Factory Certification
10. SF State biology department receives $1.5 million to support science teaching
11. Dr. Karen Lloyd receives WHOIs Holger W. Jannasch Visiting Scholar Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2016)... , PROVO and ... -- Newborn Screening Ontario (NSO), which operates the highest ... for molecular testing, and Tute Genomics and UNIConnect, leaders ... technology respectively, today announced the launch of a project ... sequencing (NGS) testing panel. NSO has ...
(Date:3/17/2016)... 17, 2016 ABI Research, the leader ... global biometrics market will reach more than $30 ... from 2015. Consumer electronics, particularly smartphones, continue to ... anticipated to reach two billion shipments by 2021 ... Pavlakis , Research Analyst at ABI Research. "Surveillance ...
(Date:3/14/2016)... Florida , March 14, 2016 ... the growing mobile commerce market, announces the airing of a ... channels starting the week of March 21 st .  The ... CNBC, including its popular Squawk on the Street show. ... focused on the growing mobile commerce market, announces the airing ...
Breaking Biology News(10 mins):
(Date:5/27/2016)... ... May 27, 2016 , ... PBI-Gordon Corporation is pleased to announce Dave ... In his 15-year career with PBI-Gordon, Dave has served in a wide variety of ... in the development and launch of many of PBI-Gordon’s most successful products. , “Dave ...
(Date:5/27/2016)... , May 27, 2016 At present, ... playing in this space know that volatility is what makes ... companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: SNTA ... Inc. (NASDAQ: LPTN ), and Heat Biologics Inc. ... access to the technical alerts for these stocks at: ...
(Date:5/26/2016)... May 26, 2016 Q BioMed Inc. ... will be a featured presenter at the 5th Annual Marcum ... New York City at the Grand Hyatt Hotel. ... Q BioMed Inc. CEO, is scheduled to begin at 11a.m ... company,s business strategy, recent developments and outline milestones for the ...
(Date:5/26/2016)... CA (PRWEB) , ... May 26, 2016 , ... ... and manufacturing company, today announced several positive developments that position the Company for ... a result of the transaction, Craig F. Kinghorn has been appointed Chairman of ...
Breaking Biology Technology: